Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0007634,
umls-concept:C0012920,
umls-concept:C0024660,
umls-concept:C0086418,
umls-concept:C0205217,
umls-concept:C0205263,
umls-concept:C0205314,
umls-concept:C0205322,
umls-concept:C0243072,
umls-concept:C0596402,
umls-concept:C0679622,
umls-concept:C0699790,
umls-concept:C1704241,
umls-concept:C1998793
|
pubmed:issue |
1
|
pubmed:dateCreated |
1997-8-8
|
pubmed:abstractText |
An alkylating camptothecin (CPT) derivative, 7-chloromethyl-10,11-methylenedioxy-camptothecin (7-CM-MDO-CPT) was recently shown to produce irreversible topoisomerase I (top1) cleavage complexes by binding to the +1 base of the scissile strand of a top1 cleavage site. We demonstrate that 7-CM-EDO-CPT (7-chloromethyl-10,11-ethylenedioxy-camptothecin) also induces irreversible top1-DNA complexes. 7-CM-MDO-CPT, 7-CM-EDO-CPT, and the nonalkylating derivative 7-ethyl-10,11-methylenedioxy-camptothecin (7-E-MDO-CPT) also induced reversible top1 cleavable complexes, which were markedly more stable to salt-induced reversal than those induced by 7-ethyl-10-hyroxy-CPT, the active metabolite of CPT-11. This greater stability of the top1 cleavable complexes was contributed by the 7-alkyl and the 10,11-methylene- (or ethylene-) dioxy substitutions. Studies in SW620 cells showed that 7-E-MDO-CPT, 7-CM-MDO-CPT, and 7-CM-EDO-CPT are more potent inducers of cleavable complexes and more cytotoxic than CPT. The reversal of the cleavable complexes induced by 7-E-MDO-CPT, 7-CM-MDO-CPT, and 7-CM-EDO-CPT was markedly slower after drug removal than that for CPT, which is consistent with the data with purified top1. By contrast to CPT, 7-E-MDO-CPT, 7-CM-MDO-CPT, and 7-CM-EDO-CPT were cytotoxic irrespective of the presence of 10 microM aphidicolin. These results suggest that 7-E-MDO-CPT, 7-CM-MDO-CPT, and 7-CM-EDO-CPT are more potent top1 poisons than CPT and produce long lasting top1 cleavable complexes and greater cytotoxicity than CPT in cells.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0026-895X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
52
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
82-7
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9224816-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:9224816-Aphidicolin,
pubmed-meshheading:9224816-Base Sequence,
pubmed-meshheading:9224816-Camptothecin,
pubmed-meshheading:9224816-Colonic Neoplasms,
pubmed-meshheading:9224816-DNA Damage,
pubmed-meshheading:9224816-DNA Topoisomerases, Type I,
pubmed-meshheading:9224816-Humans,
pubmed-meshheading:9224816-Molecular Sequence Data,
pubmed-meshheading:9224816-Structure-Activity Relationship,
pubmed-meshheading:9224816-Tumor Cells, Cultured
|
pubmed:year |
1997
|
pubmed:articleTitle |
Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells.
|
pubmed:affiliation |
Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4255, USA.
|
pubmed:publicationType |
Journal Article
|